Global Fabry Disease Treatment Market Growth (Status and Outlook) 2023-2029

Global Fabry Disease Treatment Market Growth (Status and Outlook) 2023-2029

Fabry disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha galactosidase enzyme resulting in progressive organ dysfunction. This disease is caused by abnormal buildup of a specific fatty matter called globotriaosylceramide in multiple tissues of the body including eyes, skin, kidney, gastrointestinal system, brain, heart, and central nervous system.

LPI (LP Information)' newest research report, the “Fabry Disease Treatment Industry Forecast” looks at past sales and reviews total world Fabry Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Fabry Disease Treatment sales for 2023 through 2029. With Fabry Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Fabry Disease Treatment industry.

This Insight Report provides a comprehensive analysis of the global Fabry Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Fabry Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Fabry Disease Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Fabry Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Fabry Disease Treatment.

The global Fabry Disease Treatment market size is projected to grow from US$ 1498.9 million in 2022 to US$ 2195.2 million in 2029; it is expected to grow at a CAGR of 5.6% from 2023 to 2029.

United States market for Fabry Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Fabry Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Fabry Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Fabry Disease Treatment players cover Sanofi S.A., Takeda, Amicus Therapeutics Inc., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Protalix Biotherapeutics Inc., Idorsia Pharmaceuticals Ltd., Avrobio Inc. and Greenovation Biotech GmbH, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Fabry Disease Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Enzyme Replacement Therapy (ERT)
Chaperone Treatment
Substrate Reduction Therapy (SRT)
Others

Segmentation by application
Hospital
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi S.A.
Takeda
Amicus Therapeutics Inc.
ISU Abxis Co Ltd.
JCR Pharmaceuticals Co Ltd.
Protalix Biotherapeutics Inc.
Idorsia Pharmaceuticals Ltd.
Avrobio Inc.
Greenovation Biotech GmbH
Moderna Therapeutics Inc.
Green Cross Pharma Pte Ltd.

Please note: The report will take approximately 2 business days to prepare and deliver.